In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin, Amgen of US Terminate License Agreement for Mogamulizumab
April 21, 2014
- Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat
April 18, 2014
- Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
- “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
April 18, 2014
- Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
April 18, 2014
- Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
April 17, 2014
- Metal Found in Voltaren Product Again: Novartis
April 17, 2014
- AZ Offers Sales Rep Jobs to over 100 New Graduates in FY2014
April 16, 2014
- Eisai President Naito Awarded Honorary KBE
April 16, 2014
- FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
- Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
- Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
April 14, 2014
- Patient Enrollment for PI Trial of Anticancer Drug HF10 in US Completed, Takara Bio
April 14, 2014
- RaQualia, Asahi Kasei Pharma Conclude Joint Drug Discovery Research
April 14, 2014
- 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
- Chugai Files NDA for Vemurafenib for Melanoma with BRAF Mutation, Roche Diagnostics Files for Companion Diagnostics
April 11, 2014
- 17 Patients Who Took Xeplion Have Died since November Launch
April 10, 2014
- Kyowa Kirin Completes Biopharmaceutical API Manufacturing Facility, Eying Start of Operations from 2016
April 10, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
April 9, 2014
- US Jury Orders Takeda to Pay US$6 Billion in Punitive Damages
April 9, 2014
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…